Notice of meeting, 22873-22874 [2019-10445]

Download as PDF khammond on DSKBBV9HB2PROD with NOTICES Federal Register / Vol. 84, No. 97 / Monday, May 20, 2019 / Notices Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–827–2864, maskerib@ mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Musculoskeletal, Oral, Skin, Rheumatology and Rehabilitation Sciences AREA (R15) Review. Date: June 14, 2019. Time: 10:30 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Aftab A. Ansari, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, 301–237– 9931, ansaria@csr.nih.gov. Name of Committee: Vascular and Hematology Integrated Review Group; Hemostasis and Thrombosis Study Section. Date: June 17, 2019. Time: 7:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: Wyndham Grand Chicago Riverfront, 71 E Wacker Dr., Chicago, IL 60601. Contact Person: Bukhtiar H. Shah, DVM, Ph.D., Scientific Review Officer, Vascular and Hematology IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4120, MSC 7802, Bethesda, MD 20892, (301) 806–7314, shahb@csr.nih.gov. Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Biobehavioral Mechanisms of Emotion, Stress and Health Study Section. Date: June 17–18, 2019. Time: 8:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: Ritz Carlton Hotel, 1150 22nd Street, NW, Washington, DC 20037. Contact Person: Benjamin Greenberg Shapero, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, Bethesda, MD 20892, shaperobg@mail.nih.gov. Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group; Lung Injury, Repair, and Remodeling Study Section. Date: June 17–18, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: The Westgate Hotel, 1055 Second Avenue, San Diego, CA 92101. Contact Person: Ghenima Dirami, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4122, MSC 7814, Bethesda, MD 20892, 240–498– 7546, diramig@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Mechanisms of Cancer Therapeutics 2. Date: June 17–18, 2019. VerDate Sep<11>2014 16:41 May 17, 2019 Jkt 247001 Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW, Washington, DC 20015. Contact Person: Careen K. Tang-Toth, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, (301) 435– 3504, tothct@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Cancer Drug Development and Therapeutics. Date: June 17–18, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Wyndham Grand Chicago Riverfront, 71 E Wacker Dr., Chicago, IL 60601. Contact Person: Lilia Topol, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD 20892, 301–451– 0131, ltopol@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Neurodevelopment, Synaptic Plasticity and Neurodegeneration. Date: June 17–18, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Wyndham Grand Chicago Riverfront, 71 E Wacker Dr., Chicago, IL 60601. Contact Person: Mary Schueler, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5214, MSC 7846, Bethesda, MD 20892, 301–451– 0996, marygs@csr.nih.gov. Name of Committee: Oncology 1—Basic Translational Integrated Review Group; Tumor Cell Biology Study Section. Date: June 17–18, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria, VA 22314. Contact Person: Charles Morrow, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6202, MSC 7804, Bethesda, MD 20892, 301–408– 9850, morrowcs@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Stress, Emotion, and Health. Date: June 17, 2019. Time: 4:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Ritz Carlton Hotel, Washington, DC 20037. Contact Person: Maribeth Champoux, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, MSC 7759, Bethesda, MD 20892, 301–594– 3163, champoum@csr.nih.gov. PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 22873 Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 18– 349: Short-term Mentored Career Enhancement. Date: June 17, 2019. Time: 5:00 p.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: Ritz Carlton Hotel, 1150 22nd Street, NW, Washington, DC 20037. Contact Person: Benjamin Greenberg Shapero, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, Bethesda, MD 20892, shaperobg@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: May 14, 2019. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–10363 Filed 5–17–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Notice of meeting Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene via in person and web conference on June 11, 2019, from 9:30 a.m. EDT to 4:30 p.m. EDT, and June 12, 2019, from 9:00 a.m. EDT to 4:00 p.m. EDT. The Board will meet in open-session in-person on June 11, 2019, from 9:30 a.m. EDT to 4:30 p.m. EDT and on June 12, 2019, from 9:00 a.m. EDT to 10:00 a.m. EDT to discuss the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (urine specimens) with updates from the Department of Transportation, Nuclear Regulatory Commission, and the Departmetment of Defense. There will be additional presentations from the Division of Workplace Programs’ staff on urine, oral fluid, hair Mandatory Guidelines, emerging issues surrounding marijuana legalization, and latest studies from the Behavioral Pharmacology Research Unit (BPRU). The board will meet in closed-session in-person on June 12, 2019, from 10:00 a.m. EDT to 4:00 p.m. EDT to discuss confidential issues surrounding the E:\FR\FM\20MYN1.SGM 20MYN1 22874 Federal Register / Vol. 84, No. 97 / Monday, May 20, 2019 / Notices proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (urine specimens, oral fluid, hair), invalids, studies from Johns Hopkins BPRU, impact of cannabis laws on drug testing and future direction, potential recommendations to the Assistant Secretary for Mental Health and Substance Use regarding additional drugs that may be tested for in the future, and lastly, program financials. Therefore, June 12, 2019, from 10:00 a.m. EDT to 4:00 p.m. EDT meeting is closed to the public, as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d). Meeting registration information can be completed at https:// snacregister.samhsa.gov/ MeetingList.aspx. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, https://www.samhsa.gov/ about-us/advisory-councils/meetings or by contacting the Designated Federal Officer, Matthew Aumen. Committee Name: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, Drug Testing Advisory Board. Dates/Time/Type: June 11, 2019, from 9:30 a.m. to 4:30 p.m. EDT: OPEN, June 12, 2019, from 9:00 a.m. to 10:00 a.m. EDT: OPEN, June 12, 2019, from 10:00 a.m. to 4:00 p.m. EDT: CLOSED. Place: Hilton Washington DC/ Rockville Hotel & Executive Meeting Center, 1750 Rockville Pike, Rockville, MD 20852. Contact: Matthew Aumen, Program Analyst, Center for Substance Abuse Prevention, 5600 Fishers Lane, Room 16E61A, Rockville, Maryland 20857, Telephone: (240) 276–2419, Email: matthew.aumen@samhsa.hhs.gov. Charles LoDico, Chemist. khammond on DSKBBV9HB2PROD with NOTICES [FR Doc. 2019–10445 Filed 5–17–19; 8:45 am] BILLING CODE 4162–20–P VerDate Sep<11>2014 16:41 May 17, 2019 Jkt 247001 DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency [Docket ID FEMA–2019–0002; Internal Agency Docket No. FEMA–B–1927] Proposed Flood Hazard Determinations Federal Emergency Management Agency, DHS. ACTION: Notice. AGENCY: Comments are requested on proposed flood hazard determinations, which may include additions or modifications of any Base Flood Elevation (BFE), base flood depth, Special Flood Hazard Area (SFHA) boundary or zone designation, or regulatory floodway on the Flood Insurance Rate Maps (FIRMs), and where applicable, in the supporting Flood Insurance Study (FIS) reports for the communities listed in the table below. The purpose of this notice is to seek general information and comment regarding the preliminary FIRM, and where applicable, the FIS report that the Federal Emergency Management Agency (FEMA) has provided to the affected communities. The FIRM and FIS report are the basis of the floodplain management measures that the community is required either to adopt or to show evidence of having in effect in order to qualify or remain qualified for participation in the National Flood Insurance Program (NFIP). In addition, the FIRM and FIS report, once effective, will be used by insurance agents and others to calculate appropriate flood insurance premium rates for new buildings and the contents of those buildings. SUMMARY: Comments are to be submitted on or before August 19, 2019. ADDRESSES: The Preliminary FIRM, and where applicable, the FIS report for each community are available for inspection at both the online location https://www.fema.gov/ preliminaryfloodhazarddata and the respective Community Map Repository address listed in the tables below. Additionally, the current effective FIRM and FIS report for each community are accessible online through the FEMA Map Service Center at https:// msc.fema.gov for comparison. You may submit comments, identified by Docket No. FEMA–B–1927, to Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, DATES: PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 (202) 646–7659, or (email) patrick.sacbibit@fema.dhs.gov. Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646–7659, or (email) patrick.sacbibit@fema.dhs.gov; or visit the FEMA Map Information eXchange (FMIX) online at https:// www.floodmaps.fema.gov/fhm/fmx_ main.html. SUPPLEMENTARY INFORMATION: FEMA proposes to make flood hazard determinations for each community listed below, in accordance with section 110 of the Flood Disaster Protection Act of 1973, 42 U.S.C. 4104, and 44 CFR 67.4(a). These proposed flood hazard determinations, together with the floodplain management criteria required by 44 CFR 60.3, are the minimum that are required. They should not be construed to mean that the community must change any existing ordinances that are more stringent in their floodplain management requirements. The community may at any time enact stricter requirements of its own or pursuant to policies established by other Federal, State, or regional entities. These flood hazard determinations are used to meet the floodplain management requirements of the NFIP and are used to calculate the appropriate flood insurance premium rates for new buildings built after the FIRM and FIS report become effective. The communities affected by the flood hazard determinations are provided in the tables below. Any request for reconsideration of the revised flood hazard information shown on the Preliminary FIRM and FIS report that satisfies the data requirements outlined in 44 CFR 67.6(b) is considered an appeal. Comments unrelated to the flood hazard determinations also will be considered before the FIRM and FIS report become effective. Use of a Scientific Resolution Panel (SRP) is available to communities in support of the appeal resolution process. SRPs are independent panels of experts in hydrology, hydraulics, and other pertinent sciences established to review conflicting scientific and technical data and provide recommendations for resolution. Use of the SRP only may be exercised after FEMA and local communities have been engaged in a collaborative consultation process for at least 60 days without a mutually acceptable resolution of an appeal. Additional information regarding the SRP process can be found FOR FURTHER INFORMATION CONTACT: E:\FR\FM\20MYN1.SGM 20MYN1

Agencies

[Federal Register Volume 84, Number 97 (Monday, May 20, 2019)]
[Notices]
[Pages 22873-22874]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10445]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Notice of meeting

    Pursuant to Public Law 92-463, notice is hereby given that the 
Substance Abuse and Mental Health Services Administration's (SAMHSA) 
Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory 
Board (DTAB) will convene via in person and web conference on June 11, 
2019, from 9:30 a.m. EDT to 4:30 p.m. EDT, and June 12, 2019, from 9:00 
a.m. EDT to 4:00 p.m. EDT.
    The Board will meet in open-session in-person on June 11, 2019, 
from 9:30 a.m. EDT to 4:30 p.m. EDT and on June 12, 2019, from 9:00 
a.m. EDT to 10:00 a.m. EDT to discuss the proposed Mandatory Guidelines 
for Federal Workplace Drug Testing Programs (urine specimens) with 
updates from the Department of Transportation, Nuclear Regulatory 
Commission, and the Departmetment of Defense. There will be additional 
presentations from the Division of Workplace Programs' staff on urine, 
oral fluid, hair Mandatory Guidelines, emerging issues surrounding 
marijuana legalization, and latest studies from the Behavioral 
Pharmacology Research Unit (BPRU). The board will meet in closed-
session in-person on June 12, 2019, from 10:00 a.m. EDT to 4:00 p.m. 
EDT to discuss confidential issues surrounding the

[[Page 22874]]

proposed Mandatory Guidelines for Federal Workplace Drug Testing 
Programs (urine specimens, oral fluid, hair), invalids, studies from 
Johns Hopkins BPRU, impact of cannabis laws on drug testing and future 
direction, potential recommendations to the Assistant Secretary for 
Mental Health and Substance Use regarding additional drugs that may be 
tested for in the future, and lastly, program financials. Therefore, 
June 12, 2019, from 10:00 a.m. EDT to 4:00 p.m. EDT meeting is closed 
to the public, as determined by the Assistant Secretary for Mental 
Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 
552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d).
    Meeting registration information can be completed at https://snacregister.samhsa.gov/MeetingList.aspx. Web conference and call 
information will be sent after completing registration. Meeting 
information and a roster of DTAB members may be obtained by accessing 
the SAMHSA Advisory Committees website, https://www.samhsa.gov/about-us/advisory-councils/meetings or by contacting the Designated Federal 
Officer, Matthew Aumen.
    Committee Name: Substance Abuse and Mental Health Services 
Administration, Center for Substance Abuse Prevention, Drug Testing 
Advisory Board.
    Dates/Time/Type: June 11, 2019, from 9:30 a.m. to 4:30 p.m. EDT: 
OPEN, June 12, 2019, from 9:00 a.m. to 10:00 a.m. EDT: OPEN, June 12, 
2019, from 10:00 a.m. to 4:00 p.m. EDT: CLOSED.
    Place: Hilton Washington DC/Rockville Hotel & Executive Meeting 
Center, 1750 Rockville Pike, Rockville, MD 20852.
    Contact: Matthew Aumen, Program Analyst, Center for Substance Abuse 
Prevention, 5600 Fishers Lane, Room 16E61A, Rockville, Maryland 20857, 
Telephone: (240) 276-2419, Email: [email protected].

Charles LoDico,
Chemist.
[FR Doc. 2019-10445 Filed 5-17-19; 8:45 am]
 BILLING CODE 4162-20-P